Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.330 | GeneticVariation | disease | BEFREE | Most ameloblastomas (AM) in humans harbour mutually-exclusive driving mutations in BRAF, HRAS, KRAS, NRAS or FGFR2 that activate MAPK signalling, and in SMO that activates Hedgehog signalling. | 31041834 | 2019 | ||||
|
0.330 | GeneticVariation | disease | BEFREE | Recently, BRAF and SMO mutations have been reported in ameloblastomas. | 25854168 | 2015 | ||||
|
0.330 | Biomarker | disease | CTD_human | Identification of recurrent SMO and BRAF mutations in ameloblastomas. | 24859340 | 2014 | ||||
|
0.330 | Biomarker | disease | BEFREE | Overexpression of upstream (PTCH1 and SMO) and downstream (GLI1, CCND1 and BCL2) genes in the SHH pathway leads to the constitutive activation of this pathway in KOT and AB and may suggest a mechanism for the development of these types of tumors. | 24930892 | 2014 |